BofA raised the firm’s price target on Akero Therapeutics (AKRO) to $64 from $63 and keeps a Buy rating on the shares. Akero’s Q1 print was “unsurprisingly quiet,” taking a backseat to other updates as FGF21 agonist efruxifermin continues to advance for fatty liver disease, the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Biotech Alert: Searches spiking for these stocks today
- Akero Therapeutics up 16% after Street Insider report on sale being considered
- Akero Therapeutics exploring potential sale after approach, Street Insider says
- Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target
- Akero Therapeutics price target lowered to $78 from $80 at Citi